VanEck Biotech ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Biotech ETF BBH
Morningstar’s Analysis BBH
Will BBH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 72.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Amgen Inc | 15.57 | 74M | Healthcare |
Gilead Sciences Inc | 13.32 | 64M | Healthcare |
Vertex Pharmaceuticals Inc | 8.13 | 39M | Healthcare |
Regeneron Pharmaceuticals Inc | 6.43 | 31M | Healthcare |
Moderna Inc | 6.08 | 29M | Healthcare |
Natera Inc | 5.39 | 26M | Healthcare |
argenx SE ADR | 4.57 | 22M | Healthcare |
IQVIA Holdings Inc | 4.42 | 21M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 4.32 | 21M | Healthcare |
Illumina Inc | 4.01 | 19M | Healthcare |